This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.

Elderly woman looking into the distance and smiling

 

Mechanism of action

TRUQAP (capivasertib) plus fulvestrant: the first combination therapy with dual effect AKT inhibition and ER downregulation.1–3

 

 

TRUQAP plus fulvestrant is a targeted therapy that uses AKT inhibition to address treatment resistance in patients with HR+/HER2-negative aBC, offering significantly longer progression-free survival than fulvestrant alone.4*

*mPFS of TRUQAP plus fulvestrant vs placebo plus fulvestrant in the AKT pathway-altered CAPItello-291 trial population: 7.3 vs 3.1 respectively (HR 0.50, 95% CI: 0.38–0.65, P<0.001).4

Information on the safety profile of TRUQAP plus fulvestrant can be found here.

Understanding how TRUQAP
interacts with PIK3CA/AKT1/PTEN alteration-driven disease can help you to identify eligible patients
for treatment

Approximately 70% of advanced breast cancers express the hormone receptor oestrogen or progesterone (or both) and do not have HER2 overexpression
(HR+/HER2-negative).4
 
Overactivation of the AKT pathway occurs in up to half of HR+/HER2-negative breast cancers through activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes.4

The PI3K/AKT pathway comprises the PI3K, AKT and PTEN proteins where AKT is the pivotal and central node.7 The PI3K/AKT signalling pathway regulates metabolism, cell growth and cell survival.7 This pathway plays an important role in both normal and malignant cells and is therefore an attractive target for molecular therapy. This presents an important inhibition target that is able to mediate and block oncogenic signalling in PIK3CA/AKT1/PTEN-altered tumours.7

PI3K

PI3Ks comprise lipid kinases responsible for mediating important biological functions such as cell survival, differentiation

and proliferation.8

AKT

AKT activation is associated with growth factor-independent cell proliferation, resistance to apoptosis and increased invasion and cell migration.9

PTEN

PTEN has protein phosphatase and lipid phosphatase activity. PTEN negatively regulates PI3K and AKT signalling.9,10

 

 

For HR+/HER2-negative aBC, disruption of these signalling proteins leads to progression of tumours and cancer cell growth.8–10

Infographic showing the PI3K/AKT pathway and it’s role in activating specific genes Infographic showing the PI3K/AKT pathway and it’s role in activating specific genes

 

 

 

Effective targeting with small pharmacological inhibitors could result in efficacious treatment of cancer.9,10

 

Test all your patients diagnosed with HR+/HER2-negative aBC for PIK3CA/AKT1/PTEN alterations.

Find out more about biomarker testing

Choose a dual action treatment with TRUQAP plus fulvestrant

After exposure to 1L ET ± CDK4/6i, adaptive changes along the PI3K/AKT pathway may lead to treatment resistance and disease progression.7,11


Inhibiting the mechanisms of treatment resistance, which can result from PI3K/AKT pathway activation, can extend the duration of ET and delay

disease progression.7,11

TRUQAP plus fulvestrant has the dual effect of PI3K/AKT pathway inhibition combined with ER downregulation, delaying disease progression through inhibition of two pivotal pathways driving proliferation in breast cancer.7,11

Diagram showing the mechanism of action of Truqap plus fulvestrant Diagram showing the mechanism of action of Truqap plus fulvestrant

Adapted from TRUQAP SmPC;1 Fulvestrant SmPC;3 Miricescu D, et al. 2020;6 and Osborne CK, et al. 2011.12

Explore the efficacy of TRUQAP plus fulvestrant

Resources for you and your patients

Our comprehensive resources help support you in prescribing TRUQAP plus fulvestrant. We also have dedicated patient materials to help reassure your patients throughout their treatment journey.

Diagram showing the mechanism of action of Truqap plus fulvestrant Diagram showing the mechanism of action of Truqap plus fulvestrant
Diagram showing the mechanism of action of Truqap plus fulvestrant Diagram showing the mechanism of action of Truqap plus fulvestrant
Diagram showing the mechanism of action of Truqap plus fulvestrant Diagram showing the mechanism of action of Truqap plus fulvestrant

1L=first-line; aBC=advanced breast cancer; AKT=serine/threonine protein kinase; AKT1=serine/threonine protein kinase 1; CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; CI=confidence interval; ER=oestrogen receptor; ET=endocrine therapy; HER2=human epidermal growth factor receptor 2; HR=hazard ratio; HR+=hormone receptor positive; mPFS=median progression-free survival; mTORC1=mammalian target of rapamycin complex 1; PI3K=phosphoinositide 3 kinase; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN=phosphatase and tensin homologue; SmPC=Summary of Product Characteristics.

  1. TRUQAP (capivasertib) 160 mg and 200 mg. Summary of Product Characteristics.
  2. Ribas R, et al. Mol Cancer Ther. 2015;14(9):2035–2048.
  3. Faslodex (fulvestrant). Summary of Product Characteristics.
  4. Turner NC, et al. N Engl J Med. 2023;388(22):2058–2070.
  5. Chung JH, et al. Ann Oncol. 2017;28(11):2866–2873.
  6. Miricescu D, et al. Int J Mol Sci. 2020;22(1):173.
  7. Davies BR, et al. Mol Cancer Ther. 2012;11(4):873–887.
  8. Foster JG, et al. Pharmacol. Rev. 2012;64(4):1027–1054.
  9. Matsuda S, et al. The Open Medicical Chemistry Journal. 2013;7:23–29.
  10. Barrett D, et al. Paediatr. Drugs. 2012;14(5):299–316.
  11. Papadimitriou MC, et al. Biochim Biophys Acta Mol Cell Res. 2022;1869(12):119346.
  12. Osborne CK, et al. Annu Rev Med. 2011;62:233–247.

GB-68396 | April 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.